Percentage of patients requiring intervention (hospitalization or treatment for hematologic conditions) within 180 days of initial infusion
| Complication/level . | Rituximab plus chemotherapy (n = 292) . | Chemotherapy alone (n = 1429) . | Rituximab alone (n = 319) . |
|---|---|---|---|
| Hospitalization | |||
| All causes | 143/292; 49% | 689/1429; 48% | 90/319; 28% |
| Infection-related | 37/292; 13% | 191/1429; 13% | 27/319; 8.5% |
| Anemia intervention | |||
| Not preexisting | 113/188; 60% | 443/951; 47% | 40/184; 13% |
| Preexisting | 80/104; 77% | 342/478; 72% | 75/135; 55.6% |
| All patients | 193/292; 66% | 785/1429; 55% | 115/319; 36% |
| Thrombocytopenia intervention | |||
| Not preexisting | 8.1% | 63/1275; 4.9% | < 3.5% |
| Preexisting | 22% | 26/154; 17% | 7.4% |
| All patients | 28/292; 9.6% | 89/1429; 6.2% | 11/319; 3.5% |
| Neutropenia intervention | |||
| Not preexisting | 23% | 187/1380; 14% | 1.3% |
| Preexisting | 33% | 15/49; 31% | 33% |
| All patients | 67/292; 23% | 202/1429; 14% | < 3.5% |
| Complication/level . | Rituximab plus chemotherapy (n = 292) . | Chemotherapy alone (n = 1429) . | Rituximab alone (n = 319) . |
|---|---|---|---|
| Hospitalization | |||
| All causes | 143/292; 49% | 689/1429; 48% | 90/319; 28% |
| Infection-related | 37/292; 13% | 191/1429; 13% | 27/319; 8.5% |
| Anemia intervention | |||
| Not preexisting | 113/188; 60% | 443/951; 47% | 40/184; 13% |
| Preexisting | 80/104; 77% | 342/478; 72% | 75/135; 55.6% |
| All patients | 193/292; 66% | 785/1429; 55% | 115/319; 36% |
| Thrombocytopenia intervention | |||
| Not preexisting | 8.1% | 63/1275; 4.9% | < 3.5% |
| Preexisting | 22% | 26/154; 17% | 7.4% |
| All patients | 28/292; 9.6% | 89/1429; 6.2% | 11/319; 3.5% |
| Neutropenia intervention | |||
| Not preexisting | 23% | 187/1380; 14% | 1.3% |
| Preexisting | 33% | 15/49; 31% | 33% |
| All patients | 67/292; 23% | 202/1429; 14% | < 3.5% |
Unadjusted hematologic results stratified by whether each condition was present at the initiation of infused therapy (ie, “preexisting”). Patients using rituximab monotherapy may be very different, and direct comparison with the other groups may not be appropriate. Cell with counts < 11 are suppressed in compliance with the NCI data use agreement for small cell sizes.